Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;20(3):169-171.

Corticosteroid-Free Remission in Patients With Inflammatory Bowel Disease

Bruno César da Silva  1
Affiliations

Corticosteroid-Free Remission in Patients With Inflammatory Bowel Disease

Bruno César da Silva. Gastroenterol Hepatol (N Y). 2024 Mar.
No abstract available

PubMed Disclaimer

References

    1. George J, Singh S, Dulai PS et al. Corticosteroid-free remission vs overall remission in clinical trials of moderate-severe ulcerative colitis and Crohn’s disease. Inflamm Bowel Dis. 2020;26(4):515–523. - PMC - PubMed
    1. Loftus EV, Jr, Panés J, Lacerda AP et al. Upadacitinib induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2023;388(21):1966–1980. - PubMed
    1. Loftus EV, Jr, Sands BE, Colombel JF et al. Sustained corticosteroid-free clinical remission during vedolizumab maintenance therapy in patients with ulcerative colitis on stable concomitant corticosteroids during induction therapy: a post hoc analysis of GEMINI 1. Clin Exp Gastroenterol. 2020;13:211–220. - PMC - PubMed
    1. Sandborn WJ, Feagan BG, D’Haens G et al. True North Study Group. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2021;385(14):1280–1291. - PubMed
    1. Sandborn WJ, Feagan BG, Marano C et al. PURSUIT-Maintenance Study Group. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):96–109.e1. - PubMed

LinkOut - more resources